Zhenzhen Wang
4 Papers
Zhenzhen Wang is an academic researcher. The author has contributed to research in topics: Medicine & Cancer research. The author has co-authored 3 publications.
Chat about Author
Papers
4-1BB-Based CAR T Cells Effectively Reverse Exhaustion and Enhance the Anti-Tumor Immune Response through Autocrine PD-L1 scFv Antibody
Kwang-Ting Cheng,Xiangming Feng,Zhirong Chai,Zhenzhen Wang,Zheng Liu,Zhanchao Yan,Yanming Wang,Shoutao Zhang +7 more
TL;DR: In this paper , CAR T cells with autocrine PD-L1 scFv antibody demonstrate enhanced anti-tumor activity in solid tumors and hematologic malignancies by blocking the PD-1/PD-L 1 signaling.
A HER2-targeted antibody-novel DNA topoisomerase I inhibitor conjugate induces durable adaptive antitumor immunity by activating dendritic cells
Xiaoding Tan,Peng Fang,Kai-Yang Li,Meng You,Hui Xu,Lu Wang,Lei Shi,Dong-An Yu,Zhenzhen Wang,Da-Ke Liu,Hui Shen,Wei Zhou,Maomao An +12 more
TL;DR: In this paper , a DNA topoisomerase I inhibitor, trastuzumab-L6, was designed and developed to induce immunogenic cell death in a syngeneic tumor model with a mouse cell line that expressed human HER2.
6
Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E-based Antibody-Drug Conjugate for treatment of Nectin-4-expressing Cancers.
Wei Zhou,Peng Fang,Dong-An Yu,Meng You,Long Yin,Fei Mei,Zhenzhen Wang,Hui Xu,Xiaohong Xu,Jianjun Bi,Jin Wang,Lanping Ma,Xin Wang,Lin Chen,Yonglian Zhang,Xiaowei Cen,Xi Zhu,Liguang Lou,Datao Liu,Xiaoding Tan,Jinliang Yang,Tao Meng,Jingkang Shen +22 more
TL;DR: A second generation nectin-4-specific drug, 9MW2821, based on interchain disulfide drug conjugate technology was proposed in this article , which contained a site-specifically conjugated humanized antibody and the cytotoxic moiety monomethyl auristatin E.
Overcoming multidrug resistance in gastrointestinal cancers with a CDH17-targeted ADC conjugated to a DNA topoisomerase inhibitor.
Rui Wang,Peng Fang,Xi Chen,Jiali Ji,Dongan Yu,Fei Mei,Zhenzhen Wang,Wei Zhou,Rongjuan Wang,Jian Wang,Hai Wu,Xiaoding Tan,Xun Gui +12 more
Abstract: Summary Cadherin 17 (CDH17) has emerged as a promising target for gastrointestinal (GI) cancers, which are often complicated by multidrug resistance (MDR) and recurrence. In this study, we developed 7MW4911, a CDH17-targeted antibody-drug conjugate (ADC) that incorporates a topoisomerase inhibitor MF-6 (Topi MF-6) payload linked via a cleavable linker, designed specifically to address MDR in GI cancers. 7MW4911 exhibited high specificity for CDH17-expressing cancer cells and potent cytotoxicity in vitro. In preclinical models, including patient-derived xenografts (PDXs) with distinct mutations, 7MW4911 achieved tumor growth inhibition ranging from 71% to 99%. Remarkably, 7MW4911 outperformed monomethyl auristatin E (MMAE)-based and Deruxtecan (DXd)-based ADCs in MDR models, highlighting its effectiveness against drug-resistant cancer phenotypes. Additionally, 7MW4911 showed favorable pharmacokinetics and a highest non-severely toxic dose (HNSTD) exceeding 20 mg/kg in cynomolgus monkeys, underscoring its promising safety profile. Together, these findings position 7MW4911 as a promising ADC candidate capable of enhancing therapeutic outcomes in GI cancers.